Logo
x

Search

Subscribe Now

henlius

Accord Healthcare (Intas) Receives EC Approval for Hetronifly (Serplulimab) as 1L Treatment of ES-SCLC

Accord Healthcare (Intas) Receives EC Approval for Hetronifly (Serplulimab) as 1L Treatment of ES-SCLC

  • February 6, 2025
Henlius and Intas’ Hetronifly (Serplulimab) Receives the CHMP’s Positive Opinion to Treat Extensive-Stage SCLC

Henlius and Intas’ Hetronifly (Serplulimab) Receives the CHMP’s Positive Opinion to Treat Extensive-Stage SCLC

  • October 23, 2024
Henlius and Sermonix Partner to Develop Lasofoxifene for Breast Cancer

Henlius and Sermonix Partner to Develop Lasofoxifene for Breast Cancer

  • January 11, 2024
Henlius Announces the Acceptance of NDA Application by NMPA for Hansizhuang to Treat Esophageal cancer

Henlius Announces the Acceptance of NDA Application by NMPA for Hansizhuang to Treat Esophageal cancer

  • December 13, 2023
Henlius Expands its Collaboration with Accord Healthcare to Launch Hansizhuang (serplulimab injection) in Europe and India for Various Indications

Henlius Expands its Collaboration with Accord Healthcare to Launch Hansizhuang (serplulimab injection) in Europe and India for Var...

  • October 30, 2023
Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma

Henlius Reports the NMPA Acceptance of NDA for Hansizhuang (serplulimab) to Treat Esophageal Squamous Cell Carcinoma

  • September 25, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.